

Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder

Bo Chen¹, Qian Wu¹, Gaotan Ke², Bitao Bu^{1,*}

¹Department of Neurology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

²Department of Radiology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

*Correspondence and requests for materials should be addressed to B. T. B. (bubitao@tjh.tjmu.edu.cn)

Patients	Gender	Onset age	Attack points (patients were prescribed tacrolimus at time 0, relapse after tacrolimus was marked by red)	Total number of attacks	Number of attacks before tacrolimus treatment	Number of attacks after tacrolimus treatment	ARR before tacrolimus	ARR after tacrolimus	EDSS before tacrolimus	EDSS after tacrolimus	AQP4-ab titer in serum
25	F	55	-13,-2,0,34	3	3	0	2.77	0.00	5	3	1:32
24	F	30	-3,6,32	3	1	2	4.00	0.75	9	3	1:320
23	F	19	-42,-11,27	2	2	0	0.57	0.00	4	3	1:100
22	F	6	-38,-15,-8,0,25	4	4	0	1.26	0.00	3	0	1:32
21	F	22	-3,17	1	1	0	4.00	0.00	6	1	1:32
20	F	22	-31,-23,-18,-15,-11,-7,-5,-3,-1,7,13,15	11	9	2	3.48	1.60	3	3	1:10
19	F	21	-4,-1,14	2	2	0	6.00	0.00	4	0	1:32
18	F	50	-17,-1,14	2	2	0	1.41	0.00	4	3	1:32
17	F	51	-17,-14,-3,0,13	4	4	0	2.82	0.00	6	1	1:32
16	M	47	-31,-24,-13,-1,13	4	4	0	1.55	0.00	4	2	1:10
15	F	16	-28,-25,-16,0,12	4	4	0	1.71	0.00	6	4	0
14	F	48	-19,-1,4,12	3	2	1	1.57	1.00	3	3	1:64
13	F	35	-5,-1,11	3	2	1	4.80	1.09	4	3	0
12	F	40	-3,10	1	1	0	4.00	0.00	3	3	1:64
11	F	41	-24,-20,-16,-8,-1,10	5	5	0	2.50	0.00	3	1	1:100
10	F	23	-44,-20,-12,-1,9	4	4	0	1.09	0.00	6.5	1.5	1:10
9	F	50	-4,-2,9	2	2	0	6.00	0.00	2	1	1:100
8	F	40	-3,8	1	1	0	4.00	0.00	7	1	1:100
7	F	36	-24,-18,-8,0,3,8	5	4	1	2.00	1.50	3	3	1:100
6	M	31	-17,-2,7	2	2	0	1.41	0.00	3	1	1:32
5	F	19	23,0,7	9	8	1	1.52	1.71	4.5	10	1:100
4	F	22	-2,7	1	1	0	6.00	0.00	3	0	0
3	F	17	-99,-15,-11,0,5,6	5	4	1	0.48	2.00	5	3	1:64
2	F	49	-5,6	1	1	0	2.40	0.00	7.5	3	1:10
1	F	22	-2,6	1	1	0	6.00	0.00	5	2	1:320

Patients	Dose of prednisone (6 months later)/mg	Time points of last follow-up (black) or first relapse after tacrolimus (red)	Previous therapy	Dose of tacrolimus/mg	Follow-up	Abbreviations
25	0	34		2		ARR: annualized relapse rate
24	0	6		3		EDSS: Expanded Disability Severity
23	7.5	27		2.5		CTX: cyclophosphamide
22	5	25		1		PE: Plasmapheresis
21	0	17	CTX*5d	3		AZA: azathioprine
20	10	7	PE*3	3	herpes zoster	MMF: mycophenolate mofetil
19	10	14		3		IF: interferon-beta
18	0	14		2		IVIG: intravenous immunoglobulins G
17	10	13	AZA*1m,	2		d: day
16	0	13		3		m: month
15	0	12	IF*10m	2		
14	15	4	IVIG*5d	2		
13	5	11		3		
12	0	10		2		
11	0	10	PE*3	3		
10	10	9	AZA*18m, 2	3	rash	
9	10	9		3		
8	10	8	AZA*2m,	2	hand tremor	
7	15	3		3		
6	0	7		3		
5	0	7	MMF*26M, 2	3	death	
4	7.5	7		3		
3	20	5	IVIG*5d	3		
2	10	6		3		
1	10	6		3		